A 50% stake in Oxfordshire’s Milton Park innovation campus is being brought to market for around £400M in what would be one of the UK’s largest science and innovation property deals this year.

CBRE has been appointed by Federated Hermes to sell its interest in the 302-acre park, which has a total enterprise value of about £800M. The park is jointly owned by clients of Federated Hermes and the Canada Pension Plan Investment Board, which acquired its 50% interest for about £200M in 2017.

Milton Park comprises 2.9M SF across 87 buildings and is home to more than 280 science, technology and logistics occupiers. It includes more than 1.2M SF of industrial and logistics space, 638K SF of laboratories and more than 500K SF of offices.

Occupiers include pharmaceutical and life sciences companies such as Vertex Pharmaceuticals, Ipsen and Immunocore, alongside businesses operating in fusion energy, quantum computing, agritech, advanced engineering and logistics.

Almost 40% of occupiers are in the healthcare and life sciences sectors, while technology accounts for 13% and energy 14%, according to CBRE.

“This is an exceptionally rare opportunity to gain access to the Oxford innovation ecosystem at scale, together with a 20-year track record of very strong rental and capital growth delivered through development, asset management and placemaking,” CBRE Executive Director Andrew Hawkins said in a statement.

“It will suit those with clear, long-term ambitions centred around Oxford’s impressive record of science, technology and innovation growth.”

The park is about 11 miles south of central Oxford and close to Didcot Parkway station.

It also has 22 megavolt-amperes of ring-fenced power capacity, enterprise zone status and a local development order that CBRE said could reduce the planning process for compliant proposals to 10 days.

The sale is the first time Milton Park has been openly marketed since 1984, and CBRE said demand for science and innovation space across the Golden Triangle has remained above its long-term average.

Takeup reached 441K SF in the first half of 2026, while Oxford accounted for 65% of takeup in the year to the end of the second quarter.

“Oxford has built a globally recognised life sciences cluster, but its real advantage is much broader than that with Oxford University spinouts now raising significant funding,” CBRE Head of Life Sciences Joanne Henderson said in a statement.